摘要
目的促进脑心通胶囊的临床合理应用。方法回顾性分析山东省千佛山医院收治的1例脑心通胶囊致迟发性腹型过敏性紫癜患者的治疗经过,结合世界卫生组织药品不良反应数据库及文献报道,采用诺氏评估量表判断用药与药品不良反应的相关性,并探讨其临床特点。结果患者使用脑心通胶囊后,出现阵发性腹痛伴消化道出血症状,后经甲泼尼龙片、地衣芽孢杆菌活菌胶囊、复方谷氨酰胺肠溶胶囊等对症治疗,患者皮疹明显改善,且未再出现腹痛、腹泻。患者出现严重的腹型过敏性紫癜与服用脑心通胶囊“很可能有关”(诺氏评估量表评分为6分)。结论脑心通胶囊可引起过敏性紫癜,但其药品说明书未予记载和警示。临床药师和医师应加强用药监护,同时建议药品生产厂家和广大医务工作人员应加强药物警戒,有关部门必要时修订药品说明书。
Objective To promote the rational application of Naoxintong Capsules in clinical practice.Methods The treatment process of a patient with delayed Henoch-Schonlein purpura induced by Naoxintong Capsules in the Shandong Provincial Qianfoshan Hospital was retrospectively analyzed.Based on the VigiAccess and literature,the correlation of Naoxintong Capsules with adverse drug reactions(ADRs)was evaluated by the Naranjo's ADR evaluation scale,and the clinical characteristics of this ADR were explored.Results After use of Naoxintong Capsules,the patient experienced paroxysmal abdominal pain complicated with gastrointestinal bleeding.After symptomatic treatment with Methylprednisolone Tablets,Bacillus Licheniformis Capsule,Live and Compound Glutamine Entersoluble Capsules,the patient's rash significantly improved,and she did not experienced any abdominal pain or diarrhea.The patient's severe Henoch-Schonlein purpura was likely related to Naoxintong Capsules(the score of Naranjo's ADR evaluation scale was six points).Conclusion Naoxintong Capsules can induce Henoch-Schonlein purpura,but this ADR is not recorded or warned in the drug instructions.Clinical pharmacists and physicians should strengthen pharmaceutical care,pharmaceutical manufacturers and medical staff should strengthen pharmacovigilance,and relevant departments should revise drug instructions if necessary.
作者
何芳
牟燕
韩毅
HE Fang;MU Yan;HAN Yi(Binzhou People's Hospital,Binzhou,Shandong,China 256600;The First Affiliated Hospital of Shandong First Medical University·Shandong Provincial Qianfoshan Hospital,Jinan,Shandong,China 250014)
出处
《中国药业》
CAS
2024年第2期121-124,共4页
China Pharmaceuticals
关键词
脑心通胶囊
腹型过敏性紫癜
迟发性
药品不良反应
药学监护
Naoxintong Capsules
Henoch-Schonlein purpura
delayed
adverse drug reaction
pharmaceutical care
